Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aquestive Therapeutics Inc (NQ: AQST ) 4.720 -0.280 (-5.60%) Official Closing Price Updated: 4:15 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,659,146 Open 5.130 Bid (Size) 4.720 (22) Ask (Size) 4.760 (25) Prev. Close 5.000 Today's Range 4.535 - 5.180 52wk Range 1.251 - 6.230 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day Today 8:30 EDT From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th September 09, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Performance YTD +134.83% +134.83% 1 Month +1.94% +1.94% 3 Month +82.24% +82.24% 6 Month +10.80% +10.80% 1 Year +210.53% +210.53% More News Read More Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences August 22, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™ August 14, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 06, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study July 25, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET July 23, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism June 27, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows June 25, 2024 Via Benzinga Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film June 25, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024 June 18, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities June 03, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference May 28, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference May 09, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 07, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session April 29, 2024 Via Benzinga Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film April 29, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET April 25, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday April 18, 2024 Via Benzinga Coming FDA Approvals Could Send These 3 Drug Stocks Soaring April 17, 2024 Via InvestorPlace Exposures Product Safety Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology April 12, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session April 04, 2024 Via Benzinga Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday April 04, 2024 Via Benzinga Topics Stocks Exposures US Equities Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive April 01, 2024 From Aquestive Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
